Genome editing for treating glioblastoma
A method of treating a subject who has a glioma, e.g., astrocytoma, oligodendroglioma, or glioblastoma multiforme tumor, the method comprising administering to the subject a therapeutically effective amount of a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) microRNA-10b (miR-10b) editing complex comprising a CRISPR Associated Protein 9 (Cas9) and at least one guide RNA targeting a sequence encoding miR-10b.
1. A method of treating a subject who has glioma, the method comprising administering to the subject a therapeutically effective amount of a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) microRNA-10a/microRNA-10b (miR-10a/10b) editing complex comprising a CRISPR Associated Protein 9 (Cas9) and at least one guide RNA comprising SEQ ID NO:27 or SEQ ID NO: 29;
wherein the Cas9 is administered in a viral vector comprising a sequence encoding the Cas9 protein, and the viral vector encoding the Cas 9 is selected from recombinant adenovirus and lentivirus; and
wherein the at least one guide RNA is administered in a viral vector comprising a sequence encoding the at least one gRNA, and the viral vector encoding the at least one guide RNA is selected from recombinant adenovirus and lentivirus.
2. The method of claim 1 , wherein the glioma is an astrocytoma, oligodendroglioma, or glioblastoma multiforme (GBM) tumor.
3. The method of claim 1 , wherein the viral vector encoding the Cas9 is recombinant adenovirus.
4. The method of claim 1 , wherein the viral vector encoding the Cas9 is recombinant lentivirus.
5. The method of claim 1 , wherein the viral vector encoding the at least one guide RNA is a recombinant adenovirus.
6. The method of claim 1 , wherein the viral vector encoding the at least one guide RNA is a recombinant lentivirus.
7. The method of claim 1 , wherein the complex is administered as a viral vector comprising a sequence encoding the Cas9 protein and a sequence encoding the at least one guide RNA, and the Cas9 protein and the guide RNA are expressed from the same viral vector, wherein the viral vector is an adenovirus.
8. The method of claim 1 , wherein the complex is administered as a single nucleic acid viral vector comprising a sequence encoding the Cas9 protein and a sequence encoding the at least one guide RNA, and the Cas9 protein and the at least one guide RNA are expressed from the same viral vector, wherein the viral vector is a lentivirus.
9. The method of claim 1 , wherein the Cas9 is Streptococcus thermophilus (ST) Cas9 (StCas9); Treponema denticola (TD) (TdCas9); Streptococcus pyogenes (SP) (SpCas9); Staphylococcus aureus (SA) Cas9 (SaCas9); or Neisseria meningitidis (NM) Cas9 (NmCas9), or a variant thereof.
10. The method of claim 9 , wherein the Cas9 is SpCas9 or a variant of SpCas9 selected from the group consisting of SpCas9 D1135E variant; SpCas9 VRER variant; SpCas9 EQR variant; and SpCas9 VQR variant.
11. The method of claim 1 , further comprising a guide RNA targeting miR-10b is complementary to 17-20 nucleotides of SEQ ID NO:1 or 24, and/or the guide RNA targeting miR-10a is complementary to 17-20 nucleotides of SEQ ID NO:25 or 26.
12. The method of claim 1 , wherein the CRISPR miR-10a/10b editing complex is administered systemically, locally to a tumor, or locally to the site of a tumor after complete or partial surgical resection.
13. The method of claim 1 , wherein the CRISPR miR-10a/10b editing complex is administered intrathecally.
14. The method of claim 1 , wherein the CRISPR miR-10a/10b editing complex is formulated to be administered in a composition comprising a biodegradable, biocompatible polymer.
15. The method of claim 14 , wherein the biodegradable, biocompatible polymer is selected from the group consisting of collagen, ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, polyethyleneglycol-coated liposomes, and polylactic acid.